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Abstract
The development of rapid serodiagnostic tests for sleeping sickness and other diseases
caused by kinetoplastids relies on the affordable production of parasite-specific recombi-
nant antigens. Here, we describe the production of recombinant antigens from Trypano-
soma brucei gambiense (T.b. gambiense) in the related species Leishmania tarentolae (L.
tarentolae), and compare their diagnostic sensitivity and specificity to native antigens cur-
rently used in diagnostic kits against a panel of human sera. A number of T.b. gambiense
protein antigen candidates were chosen for recombinant expression in L. tarentolae based
on current diagnostics in field use and recent findings on immunodiagnostic antigens found
by proteomic profiling. In particular, the extracellular domains of invariant surface glycopro-
tein 65 (ISG65), variant surface glycoproteins VSG LiTat 1.3 and VSG LiTat 1.5 were fused
with C-terminal histidine tags and expressed as soluble proteins in the medium of cultured,
recombinant L. tarentolae. Using affinity chromatography, on average 10 mg/L of recombi-
nant protein was purified from cultures and subsequently tested against a panel of sera
from sleeping sickness patients from controls, i.e. persons without sleeping sickness living
in HAT endemic countries. The evaluation on sera from 172 T.b. gambiense human African
trypanosomiasis (HAT) patients and from 119 controls showed very high diagnostic poten-
tial of the two recombinant VSG and the rISG65 fragments with areas under the curve
between 0.97 and 0.98 compared to 0.98 and 0.99 with native VSG LiTat 1.3 and VSG
LiTat 1.5 (statistically not different). Evaluation on sera from 78 T.b. rhodesiense HAT
patients and from 100 controls showed an acceptable diagnostic potential of rISG65 with an
area under the curve of 0.83. These results indicate that a combination of these recombi-
nant antigens has the potential to be used in next generation rapid serodiagnostic tests. In
addition, the L. tarentolae expression system enables simple, cheap and efficient produc-
tion of recombinant kinetoplatid proteins for use in diagnostic, vaccine and drug discovery
research that does not rely on animal use to generate materials.
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Author Summary
The development of rapid serodiagnostic tests for African sleeping sickness and other dis-
eases caused by kinetoplastids relies in part on the affordable production of parasite-spe-
cific recombinant antigens. The majority of cases of sleeping sickness are caused by the
parasite Trypanosoma brucei gambiense (T.b. gambiense) which is transmitted when bitten
by an infected tsetse fly. Existing tests rely on the utilisation of extracts from the parasite
or use antigens raised in animal models. In this study we have shown that using a cell cul-
ture system devised from a parasite similar to T.b. gambiense recombinant antigens can be
produced that are as effective in rapid diagnostic tests as the native antigens purified from
T.b. gambiense parasites grown in laboratory rodents. We compared the diagnostic sensi-
tivity and specificity of the antigens we produced recombinantly to native antigens cur-
rently used in diagnostic kits against a panel of human sera. The evaluation on sera from
172 T.b. gambiense patients and from 119 controls without sleeping sickness showed very
high diagnostic potential of two recombinant antigens where the response was not signifi-
cantly different to that from the native antigens. These results indicate that a combination
of these recombinant antigens has the potential to be used in next generation rapid sero-
diagnostic tests.
Introduction
Human African Trypanosomiasis (HAT), also known as African sleeping sickness, is usually a
fatal disease caused by the parasites Trypanosoma brucei gambiense (T.b. gambiense) or T.b.
rhodesiense [1–3]. The parasite is transmitted by the bite of infected tsetse flies in sub-Saharan
Africa with T.b. gambiense being responsible for 95% of the cases in West and Central Africa.
The remaining infections are caused by T.b. rhodesiense in East and Southern Africa. Although
the number of infections currently reported at less than 5,000 cases per year are not at the level
reported during the last century (300,000 per year), this disease still causes considerable suffer-
ing and burden on communities in terms of disability-adjusted life years [4,5]. The disease fol-
lows two stages where the trypanosomes are limited to the blood and lymphatic systems
initially, but in most cases will invade the central nervous system. This second stage causes
sleep cycle disruption and neurological damage leading to coma and death if not treated [6].
Diagnosis of sleeping sickness is complex as detection of the parasite in a patient is very dif-
ficult and, in the case of a positive result, involves a subsequent lumbar puncture to assess the
disease stage [7]. Following an infective bite, the patient suffers peaks of parasitaemia as the
host mounts a humoral response to the changing surface antigens on the trypanosome, in par-
ticular the variant surface glycoproteins (VSGs). Parasites attempt to evade this humoral attack
by expressing alternative VSGs (antigenic variation) and continue to multiply until the new
variable antigen type (VAT) is recognised by the host and attacked [8]. One of the most com-
mon VAT is considered to be LiTat 1.3 and its VSG is the major antigen present in the Card
Agglutination Test for Trypanosomiasis (CATT) which is currently used in large scale popula-
tion screening [9]. In the field, this is followed by a series of time-consuming parasitological
tests that often are used to reach a diagnosis by the application of a complex algorithm [10].
Recent efforts to improve diagnosis have focussed on developing rapid immunochromato-
graphy-based serodiagnostic tests (RDT’s), which as point of care tests (POCT), should follow
the WHO ASSURED criteria; affordable, sensitive, specific, user-friendly, rapid, equipment-
free and deliverable to the people at need [11]. First generation RDTs look very promising but
have lower specificity than expected when tested on a wider target area [12–14]. Current RDTs
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for HAT rely on the infection of rodents and the purification of the native VSGs LiTat 1.3 and
LiTat 1.5, which do not represent all the variants encountered in the field. Other approaches to
identifying immunodiagnostic antigens have involved soluble fractions of other native VSGs
(sVSG117) and the proteomic identification and selection of other surface antigens [15,16].
The latter has identified a number of antigens that were recognised by the sera of HAT infected
patients and in particular the invariant surface glycoprotein 65 (ISG65) showed potential,
either on its own or in combination with sVSG117. Other potential antigens could not be
expressed as recombinant proteins in E.coli and were not investigated further. However, unlike
prokaryotic expression systems, eukaryotes have the ability to carry out more complex folding
and post-translational modifications (PTMs) such as glycosylation and Pichia pastoris has
recently been used successfully to express soluble VSGs [17]. Sugar moieties are known to be
major antigenic structures by themselves and /or in combination with their folded protein part-
ner [18]. For recombinant expression the main aim is to reproducibly produce material as
close to the native type as possible without having to handle highly virulent parasites, and in
an economic system. In this study we have examined the potential application of the related
trypanosomatid organism Leishmania tarentolae (L. tarentolae) as a recombinant antigen pro-
duction system [19]. It is a Biosafety handling level one system, which can be genetically engi-
neered and scaled up to bioreactor production using readily available medium and equipment.
We have expressed, purified and compared recombinant VSG fragments from L. tarentolae,
with VSG’s purified from their native counterparts. We have also examined the potential of
rISG65 from L. tarentolae to act as an antigen in serodiagnostic tests for sleeping sickness
caused by both T.b. gambiense and T.b. rhodesiense. Testing was carried out on serum from
confirmed HAT patients and controls from a wide range of endemic areas. We show that the L.
tarentolae system can express recombinant antigens that are as effective as the native antigens
for use in RDTs for HAT, and suggest this may have a wider application as a production plat-
form of recombinant proteins for diagnostic and vaccine generation applications.
Materials and Methods
Ethics statement
Part of the serum samples used in this study were collected within a diagnostic study (Sero-
Strip) carried out in the Democratic Republic of the Congo (DRC) [13]. Permission for this
study was obtained from the national ethics committee of DRC (CNG/M.D./111/2012) and
from the ethics committee of the University of Antwerp (11435795). The other sera were
obtained from theWorld Health Organization HAT Specimen Bank [20]. The specimen collec-
tion and banking was approved by the WHO Ethical Review Committee and the different
national ethical committees in each country where specimens were collected. The National
Ministries of Health also gave their approval. All individuals gave their written informed con-
sent for the use of their plasma specimen in HAT research before providing blood. All speci-
mens were anonymised.
Specimen collection
Table 1 represents the serum collection used in this study. Serum donors were classified as HAT
patients when trypanosomes were detected in any body fluid (blood, lymph, cerebrospinal
fluid). Non-HAT controls were persons fromHAT endemic regions but without history of
HAT and without clinical, serological or parasitological evidence of infection with T.b. gam-
biense or T.b. rhodesiense. One hundred forty one sera from gambienseHAT (g-HAT) patients
and from non-g-HAT controls were collected within the SeroStrip study conducted in the DRC
[13]. Additional sera from g-HAT patients and non-g-HAT controls and from rhodesienseHAT
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(r-HAT) patients and non-r-HAT controls were received from theWorld Health Organization
HAT Specimen Bank [20] and originated from Guinea, Tchad and DRC (T.b. gambiense) and
fromMalawi and Tanzania (T.b. rhodesiense).
Constructs and expression
Peptides were identified using data from proteomic studies on proteins recognised by g-HAT
patient sera that were matched to an ISG65 from T.b. brucei (UniProt reference Q26712 and
Q58F5) [16]. Using protein-protein BLAST a 98% identical T.b. gambiense homologue (Uni-
Prot reference C9ZJ77) was selected for expression and investigation in this project. The DNA
coding for amino acid residues 19–385 of this homologue was commercially synthesized by
Gene Art (LifeTechnologies). The DNA for recombinant VSG LiTat 1.3 (UniProt reference
X5GEX5) and VSG LiTat 1.5 (UniProt reference E7EDN2) were kindly donated by S. Rogé,
ITM, Belgium [17]. It had previously been shown that N-terminal peptides contain more spe-
cific epitopes [17] so the native DNA sequences coding for amino acid residues 24–372 for
VSG LiTat1.3 and amino acids 33–426 for VSG LiTat 1.5 were used. All constructs were cloned
into the LEXSYS vector pLEX hyg2 (Jena Bioscience) in frame with the signal peptide of
secreted acid phosphatase of L.mexicana and a carboxy-terminal hexa-histidine tag within the
vector. Following electroporation of LEXSYS host strain p10, clonal isolates were selected as
previously described [19]. Production of recombinant protein was carried out in 1 litre baffled
Erlenmeyer flasks in BHI medium (supplemented with antibiotics and hemin) and the medium
was harvested when the OD600 reached 4 (approx. 70 h post inoculation, 10
8 cells/ml). All
media components were from Jena Bioscience. Clarified medium was concentrated twenty fold
on a Pellicon XL 50 Ultrafiltration cassette (10 kDa MWCO) and diluted four times in binding
buffer (20 mM Phosphate, 500 mMNaCl, 10 mM Imidazole) before addition to an equilibrated
His Trap (GE Healthcare) FPLC column. Bound proteins were eluted using an increasing
Imidazole gradient (20 mM Phosphate, 500 mM NaCl, 500 mM Imidazole). Peak protein con-
taining fractions, as determined by A280 nmmeasurement, were combined, desalted and con-
centrated by centrifugation in Amicon Ultra-15 device (30 kDa MWCO). The final protein was
stored at 1 mg/ml in solution in PBS, 15% glycerol at -20°C.
Characterisation of recombinant proteins
Following SDS-PAGE of purified recombinant proteins (Fig 1) each band was excised from the
gel, digested with Trypsin (Sigma–Aldrich, P7367) and the resulting peptides subjected to
matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-
TOF-MS. Briefly, excised bands were reduced and alkylated with iodoacetamide and digested
in-gel with trypsin (Promega V5111) as previously described [21]. The tryptic peptides (0.5 μl)
were spotted onto an MTP AnchorChip 384 T F target plate (Bruker part number 209514)
and allowed to air dry. Peptides spots were then overlaid with an equal volume of α-cyano-
Table 1. Serum collection used in this study.
T.b. gambiense T.b. rhodesiense
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4-hydroxycinnamic acid matrix (0.7 mg/ml in 85% acetonitrile, 15% water, 0.1% TFA and 1
mMNH4H2PO4, Bruker). The same volume of peptide calibration standard II mix (Bruker,
made according to the manufacturer’s instructions) was spotted in the appropriate positions
and allowed to air dry. Mass spectra were collected on an UltrafleXtreme (Bruker) instrument
and Mascot software used to match peptides to the SwissProt database.
For gel filtration experiments, purified rISG 65 (100 μl of 1 mg/ml) was applied to a gel fil-
tration Superdex 200 10/300 GL column (GE Healthcare LifeSciences) in sodium phosphate
buffer (pH7.5), 0.5 M NaCl previously calibrated with molecular weight markers (Sigma-
Aldrich MWGF100) and eluted with at a flow rate of 1 ml/min.
In order to examine the potential presence of N-linked sugars, rISG 65 (1 μg) was treated
with PNGase F (1.5 U) (Sigma-Aldrich, P7367) for two hours at 37°C using manufacturers
instructions before being analysed by SDS-PAGE to determine if this resulted in a shift in
molecular weight.
Native antigens
Native variant surface glycoprotein (VSG) was prepared following standard procedures from
cloned populations of T.b. gambiense variant antigen types (VATs) LiTat 1.3 and LiTat 1.5
[22]. After purification, the native VSG LiTat 1.3 (nLiTat 1.3) and native VSG LiTat 1.5 (nLiTat
1.5) antigens were lyophilised in aliquots of 1 mg and stored at -80°C prior to use.
ELISA
The ELISA protocol was based on the procedure according to Lejon et al. [23–25]. Microplates
(Maxisorp, Nunc) were coated overnight at 4°C with 100 μl/well of purified recombinant pro-
tein at 4 μg/ml or with native antigen at 2 μg/ml. All antigens were diluted in phosphate buffer
Fig 1. SDS-PAGE analysis of the expression of rISG65, rLiTat1.3 and rLiTat1.5 by Leishmania
tarentolae after purification following a single round of metal affinity chromatography. Coomassie
stained 10% SDS-PAGE; Precision Plus Protein Unstained Standards, BioRad (M). Lane 1: rISG65, Lane 2:
rLiTat1.3, Lane 3: rLiTat1.5. A = 1 μg and B = 10 μg protein.
doi:10.1371/journal.pntd.0004271.g001
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(PB) (10 mM sodium phosphate, pH 6.5). To correct for aspecific reactions, caused by contam-
inating L. tarentolae proteins that were not eliminated from the protein mixture by the one-
step affinity purification, control wells were coated with the supernatant of a culture of
untransfected L. tarentolae cells at 4 μg/ml. Further manipulations were undertaken at ambient
temperature. After coating, the wells were blocked with PBS-Blotto (0.01 M sodium phosphate,
0.2 M sodium chloride, 0.05% NaN3, 1% skimmed milk powder, pH 7.4) for 1 hour. Before
addition to the microplate the sera were diluted at 1:150 in PBS-Blotto. Antibody binding was
visualised with goat anti-human IgG (H+L) conjugated with horseradish peroxidase (1:40000;
Jackson ImmunoResearch) and the chromogen ABTS (2,2’-azinobis[3-ethylbenzothiazonline-
6-sulfonic acid]-diammonium salt; Roche). The optical densities (ODs) were read at 414 nm
(Multiskan RC Version 6.0; Labsystems). Corrected optical density (ODcorr) values were calcu-
lated by subtracting for each serum the OD reading in the control well from the OD reading in
the antigen coated well.
Statistical analysis
ELISA results were captured in a Microsoft Excel 2010 database. The accuracy of the different
antigens for diagnosis was determined in SigmaPlot 12.5 by calculation of the area under the
receiver operator characteristics (ROC) curve (AUC) [26]. Confidence intervals (CI) were
determined according to DeLong [27]. Sensitivities and specificities with 95% binomial Wilson
confidence intervals and the Youden index were calculated using SigmaPlot 12.5 [28]. The
McNemar Chi2 test was used to test differences in the AUCs.
Results
Production of recombinant antigens
Soluble forms of the T.b. gambiense invariant surface glycoprotein 65 (ISG65) and the variant
surface glycoproteins VSG LiTat 1.3 and VSG LiTat 1.5 (with C-terminal histidine tags remain-
ing intact) were expressed as soluble proteins in the medium of the recombinant LEXSYS host
strain p10 and purified on Ni-NTA resin. Protein purity was examined by SDS-PAGE analysis
and subsequent Coomassie blue staining of the resulting gel to visualise those protein bands
present (Fig 1). The identity of the recombinant proteins were confirmed by tryptic digestion
of the excised bands (Fig 1) followed by mass spectrometry and matching the peptides to the
protein sequence databases [29]. Recombinant constructs for the VSG LiTat1.3 and LiTat1.5
had been previously expressed in Pichia pastoris as a secreted product with evidence of post-
translational processing [17]. rLiTat1.3 has a predicted molecular mass of 38 kDa from its
amino acid sequence with 2 potential N-glycosylation sites. rLiTat1.5 is predicted to be 40.5
kDa with no potential N-glycosylation sites. The presence of two bands in the purified material
for the rVSGs is likely to arise from either different post-translational modifications of the two
species present or, possibly, be due to proteolysis as observed by Rogé et al. [17] when
expressed in Pichia pastoris. All bands were positively identified as corresponding to the
respective VSG by mass spectrometry but this data and not allow us to determine conclusively
the difference between the two bands observed. rISG65 is predicted from its amino acid
sequence to be 41.8 kDa with 2 potential N-glycosylation sites. Further analysis of the purified
rISG65 by gel chromatography confirmed the presence of a monomeric molecule of 50–60 kDa
as shown in Fig 2. Following PNGase F treatment to remove potential N-glycans, the apparent
molecular mass of rISG65 was reduced, as determined using SDS-PAGE analysis, consistent
with the presence of N-linked sugars (Fig 3).
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Diagnostic potential of the recombinant antigens for gambiense HAT
and rhodesiense HAT
The sera from 172 g-HAT patients, 119 non-g-HAT controls and 50 non-r-HAT controls were
tested by ELISA with rISG65, rLiTat 1.3, rLiTat 1.5, nLiTat 1.3 and nLiTat 1.5. With the parasi-
tological status as reference and the cut-off for each antigen set at its highest Youden index (sen-
sitivity + specificity -100), each antigen displayed a sensitivity> 92.4% and a specificity> 94%
(Table 2). The diagnostic potential of each antigen in function of varying ODcorr cut-off is repre-
sented in the Receiver Operating Curve (ROC) plots in Fig 4 showing areas under the curve
Fig 2. Gel filtration of purified rISG65 on a Superdex 200 10/300 GL column (GE Healthcare Lifesciences) in sodium phosphate buffer, pH7.5, O.5 M
NaCl. A. Molecular weight markers (Sigma-Aldrich MWGF100) 1 = thyroglobulin 669 kDa, 2 = apoferritin 443 kDa, 3 = β-amylase 200 kDa, 4 = alcohol
dehydrogenase 150 kDa, 5 = bovine serum albumin 66 kDa, 6 = carbonic anhydrase 29 kDa. B. Elution profile of rISG following one round of metal affinity
chromatography purification.
doi:10.1371/journal.pntd.0004271.g002
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(AUC) ranging from 0.97 to 0.98 for the recombinant antigens and from 0.98 to 0.99 for the
native antigens (Fig 4 and Table 2). Pairwise comparison of the AUC obtained with the different
antigens showed no statistically significant differences except between the AUC of rLiTat 1.3
and nLiTat 1.3 (Table 3).
In a similar way, the sera from 78 r-HAT patients, 50 non-r-HAT controls and 50 non-g-
HAT controls were tested in ELISA with all the antigens. The results are represented in Fig 5
as ROC plots and in Table 4. Sensitivities and specificities ranged respectively from 37.2 to
79.5% and from 76 to 90% due to the poor reactivity of the antigens with r-sera. Significant dif-
ferences in the AUC of the antigens were observed in more than half of the pairwise compari-
sons (Table 5).
Fig 3. Analysis of the deglycosylation of rISG65 using PNGase F (1.5 U) (Sigma-Aldrich, P7367) for
two hours at 37°C.Coomassie blue stained pre-cast 4–12% BisTris gradient SDS-PAGE gel (Novex) using
the MOPS running system; Precision Plus Protein Unstained Standards, BioRad (M). Lane 1: rISG65 (1 ug)
before treatment with PNGase F, Lane 2: rISG65 (1 ug) after treatment with PNGase F.
doi:10.1371/journal.pntd.0004271.g003
Table 2. Area under the curve (AUC) and its 95% confidence interval (CI), Youden index, percent sensitivity (Se %), percent specificity (Sp %) and
their respective 95% CI recorded for the different antigens when tested with sera from 172 g-HAT patients, 119 non-g- HAT controls and 50 non-r-
HAT controls.
Antigen AUC 95% CI Youden Se % 95% CI Sp % 95% CI
rISG65 0.98 0.964–0.997 0.91 92.4 87.42%–95.91% 98.8 95.79%–99.86%
rLiTat 1.3 0.97 0.950–0.989 0.88 93.0 88.13%–96.34% 94.7 90.13%–97.54%
rLiTat 1.5 0.97 0.955–0.994 0.92 95.4 91.04%–97.97% 96.5 92.43%–98.69%
nLiTat 1.3 0.99 0.971–1.0 0.94 95.4 91.04%–97.97% 98.2 94.90%–99.63%
nLiTat 1.5 0.98 0.965–0.996 0.94 97.1 93.35%–99.05% 97.0 93.23%–99.03%
doi:10.1371/journal.pntd.0004271.t002
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Discussion
As the numbers of people infected with sleeping sickness continue to fall, the targeted elimina-
tion of the disease by 2030, as suggested by WHO, is conceivable [30]. However, many obsta-
cles still need to be overcome including the development and availability of a reliable point of
care test (POCT) and the development of oral delivery drugs which can be used in the remote
Fig 4. Receiver operator characteristic (ROC) curves and area under the curve (AUC) constructed
from ELISA results obtained by testing sera from 172 g-HAT patients, 119 non-g-HAT controls and 50
non-r-HAT controls with nLiTat 1.3 (2 μg/ml), rLiTat 1.3 (4 μg/ml), nLiTat 1.5 (2 μg/ml), rLiTat 1.5 (4 μg/
ml) and rISG65 (4 μg/ml).
doi:10.1371/journal.pntd.0004271.g004
Table 3. Pairwise difference and p value of the Chi square between the areas under the curve recorded for the different antigens when tested with
sera from 172 T.b. g-HAT patients, 119 non-g-HAT controls and 50 non-r-HAT controls. * = significantly different
rLiTat 1.3 rLiTat 1.5 nLiTat 1.3 nLiTat 1.5
rISG65 0.011, p = 0.061 0.006, p = 0.291 0.005, p = 0.602 0.001, p = 0.981
rLiTat 1.3 0.005, p = 0.302 0.016, p = 0.040* 0.011, p = 0.188
rLiTat 1.5 0.011, p = 0.152 0.006, p = 0.423
nLiTat 1.3 0.005, p = 0.166
doi:10.1371/journal.pntd.0004271.t003
An RDT for Trypanosoma brucei gambiense Antigens
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004271 December 9, 2015 9 / 13
areas where foci still exist. Such an assay will become even more essential for the monitoring
and surveillance of remote areas in view of the targeted continuing decline of the prevalence. A
recent examination of the currently available RDTs for serodiagnosis of g-HAT inWest Africa
demonstrated a lower specificity than expected (88%) but suggested a parallel use of both avail-
able tests could increase specificity and sensitivity [14]. These first generation RDTs contain
native (n) nLiTat 1.3 and nLiTat 1.5 as antigens but research is ongoing to replace them by sec-
ond and future generation RDTs containing recombinant antigens. A recombinant fragment of
Fig 5. Receiver operator characteristic (ROC) curves and area under the curve (AUC) constructed
from ELISA results obtained by testing sera from 78 r-HAT patients, 50 non-r-HAT controls and 50
non-g-HAT controls with nLiTat 1.3 (2 μg/ml), rLiTat 1.3 (4 μg/ml), nLiTat 1.5 (2 μg/ml), rLiTat 1.5 (4 μg/
ml) and rISG65 (4 μg/ml).
doi:10.1371/journal.pntd.0004271.g005
Table 4. Area under the curve (AUC) and its 95% confidence interval (CI), Youden index, percent sensitivity (Se %), percent specificity (Sp %) and
their respective 95% CI recorded for the different antigens when tested with sera from 78 r-HAT patients, 50 non-r-HAT controls and 50 non-g-HAT
controls.
Antigen AUC 95% CI Youden Se % 95% CI Sp % 95% CI
rISG65 0.83 0.768–0.899 0.62 73.1 61.84%–82.50% 89.0 81.17%–94.38%
rLiTat 1.3 0.65 0.563–0.728 0.27 37.2 26.50%–48.87% 90.0 82.38%–95.10%
rLiTat 1.5 0.70 0.620–0.778 0.39 61.5 49.83%–72.34% 77.0 67.51%–84.83%
nLiTat 1.3 0.85 0.784–0.908 0.65 79.5 68.84%–87.80% 86.0 77.63%–92.13%
nLiTat 1.5 0.82 0.754–0.883 0.52 75.6 64.60%–84.65% 76.0 66.43%–83.98%
doi:10.1371/journal.pntd.0004271.t004
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ISG65 has been expressed in Escherichia coli and used as an antigen in a prototype lateral flow
device on its own [16] and in combination with native VSGs, VSG117 [15] or VSG 117 purified
from T.b. brucei [31]. Although these tests showed a good sensitivity (88% to 98% for the single
antigen device), the specificities only ranged between 65% and 93%. In the dual antigen proto-
types, the specificities varied from 83% to 97% [15,16,30]. Recombinant antigens expressed in
E. coli are not glycosylated and therefore may miss some critical epitopes with diagnostic
potential that may be present on glycosylated and correctly folded native glycoproteins, such
as ISG65. Correct glycosylation is often a requirement for proper folding of proteins and the
absence of this in E.coli expression systems is likely to lead to both incorrect folding and
absence of glycan containing epitopes. In contrast, eukaryotic expression systems, including
insect and mammalian cells, yeast and protozoa, can yield glycosylated recombinants that can
be engineered to be secreted into the culture medium [32]. The collection/harvesting of the
medium can then be used as a first step in the purification process for such recombinant
molecules.
In this study we describe the use of the L. tarentolae expression system (LEXSYS) to express
T b gambiense surface antigens as secreted recombinant molecules. The native and recombi-
nant VSG LiTat 1.5 showed comparable diagnostic accuracy when tested with g-HAT sera and
non-HAT controls in the ELISA format as did the recombinant and native VSG LiTat 1.3. This
suggests that recombinant VSG fragments could eventually replace the native forms currently
used in RDT tests thus eliminating the complex and dangerous process of purifying native anti-
gens from living, highly virulent infective parasites grown in laboratory rodents. Our results
are similar to those reported for the expression of recombinant VSG LiTat 1.3 and VSG LiTat
1.5 fragments in Pichia pastoris [17]. Although VSGs LiTat 1.3 and LiTat 1.5 are T.b. gambiense
specific and are not expressed in T.b. rhodesiense infections, both the recombinant and native
forms of VSGs LiTat 1.3 and LiTat 1.5 reacted with a considerable number of sera from r-HAT
patients yielding a sensitivity of up to 80% for native VSG LiTat 1.5. This could be due to epi-
topes on these VSG fragments that are not variant-specific but common to other variants,
including variants expressed by other subspecies of T. brucei [18]. Among the recombinant
antigens investigated here, it was rISG65 that showed the highest diagnostic potential for r-
HAT with an AUC of 0.83. As ISG65 belongs to the invariant surface glycoprotein set of T. bru-
cei the antigen should also be recognised by sera from g-HAT that do not contain antibodies
against VSG LiTat 1.3 and LiTat 1.5. However, most sera from g-HAT patients used in the cur-
rent study have been pre-selected by using CATT/T.b.gambiense as screening test during active
case detection in the field. Therefore, a carefully designed prospective study with unbiased
inclusion of participants is needed to confirm the hypothesis that rISG65 could detect patients
that are not reactive with recombinant or native VSG LiTat 1.3 or VSG LiTat 1.5.
We conclude that rLiTat 1.3, rLiTat 1.5 and rISG65 can be expressed and post-translation-
ally processed and secreted by L. tarentolae in a manner similar to the related kinetoplastid
Trypanosome species. Moreover, the ease of engineering and production of recombinant pro-
teins by this system allows for the development of tests for single or multiple diseases by
Table 5. Pairwise difference and p value of the Chi square between the areas under the curve recorded for the different antigens when tested with
sera from 78 r-HAT patients, 50 non-r-HAT controls and 50 non-g-HAT controls. * = significantly different
rLiTat 1.3 rLiTat 1.5 nLiTat 1.3 nLiTat 1.5
rISG65 0.188, p < 0.001* 0.135, p < 0.001* 0.012, p = 0.693 0.0143, p = 0.607
rLiTat 1.3 0.0531, p = 0.095 0.200, p < 0.001* 0.173, p < 0.001*
rLiTat 1.5 0.147, p < 0.001* 0.120, p = 0.001*
nLiTat 1.3 0.0265, p = 0.225
doi:10.1371/journal.pntd.0004271.t005
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combining different antigens on a single lateral flow test. We expect that rISG65, in combina-
tion with one or another recombinant VSG, will lead to the development of a powerful sero-
diagnostic test for g-HAT that will meet the ASSURED criteria for NTD diagnostics [11]. In
addition L tarentolae has the potential to be used for the expression of antigens for other
neglected tropical diseases caused by kinetidoplastid organisms as it appears to process the
recombinant proteins in the same manner as the native antigens.
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